Remibrutinib is an Orally Active BTK Inhibitor for Chronic Urticaria Research
Remibrutinib is a potent and orally active BTK inhibitor for Chronic urticaria (CU) research.
Remibrutinib is a potent and orally active BTK inhibitor for Chronic urticaria (CU) research.
Chronic urticaria is a heterogeneous, persistent, and severely debilitating disease. Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling. Especially, BTK is critical…